drugset / Trial / NCT03608839

Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial

NCT03608839 ↗

Phase 2 Completed 27 enrolled Federal University of Pernambuco
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Purpose: To determine the impact of short-term 4mg/ml dexamethasone solution treatment in diabetic macular edema (DME). Design: Phase II, randomized, prospective, parallel, interventional study. Participants: Pseudophakic patients with central-involved DME. Methods: Twenty-seven patients with visual impairment caused by DME were randomized in a 1:1:1 ratio, in order to investigate treatment with 0.01 ml, 0.03 ml and 0.05 ml intravitreous dexamethasone solutions, and followed-up over 28 days Outcome Measures: The primary outcome was macular thickness at three days after intravitreous dexamethasone. The secondary outcomes were macular thickness at 28 days after intravitreous dexamethasone, best-corrected visual acuity (BCVA) and intraocular pressure (IOP) at three and 28 days after intravitreous dexamethasone

Timeline

Start
2016-05-01
Primary completion
2017-12-20
Completion
2018-10-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 ug Intravitreal
Subject Dexamethasone Small molecule 120 ug Intravitreal
Subject Dexamethasone Small molecule 200 ug Intravitreal